Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
97.52
-0.20 (-0.20%)
At close: Dec 5, 2025, 4:00 PM EST
97.55
+0.03 (0.03%)
After-hours: Dec 5, 2025, 7:44 PM EST
| Period Ending | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiology | 10.01B | 9.50B | 8.90B | 8.35B | 7.80B | 7.32B | 6.97B | 6.71B | |||||||||||||
| Cardiology Growth | 28.40% | 29.86% | 27.65% | 24.40% | 20.24% | 15.81% | 13.75% | 13.08% | |||||||||||||
| Endoscopy | 2.85B | 2.78B | 2.72B | 2.69B | 2.64B | 2.59B | 2.55B | 2.48B | |||||||||||||
| Endoscopy Growth | 7.80% | 7.18% | 6.67% | 8.22% | 9.68% | 10.86% | 12.35% | 11.75% | |||||||||||||
| Peripheral Interventions | 2.70B | 2.60B | 2.49B | 2.41B | 2.30B | 2.23B | 2.18B | 2.11B | |||||||||||||
| Peripheral Interventions Growth | 17.54% | 16.43% | 14.41% | 14.27% | 11.99% | 12.09% | 12.55% | 11.12% | |||||||||||||
| Urology | 2.62B | 2.47B | 2.32B | 2.20B | 2.10B | 2.05B | 2.01B | 1.96B | |||||||||||||
| Urology Growth | 24.99% | 20.65% | 15.54% | 12.02% | 9.56% | 9.87% | 9.79% | 10.77% | |||||||||||||
| Neuromodulation | 1.17B | 1.14B | 1.12B | 1.11B | 1.08B | 1.04B | 998.00M | 976.00M | |||||||||||||
| Neuromodulation Growth | 8.47% | 10.14% | 12.22% | 13.22% | 12.45% | 9.28% | 5.83% | 6.32% | |||||||||||||
| Specialty Pharma | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 191.00M | 219.00M | 241.00M |
Revenue by Geography
| Period Ending | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 12.37B | 11.67B | 10.91B | 10.21B | 9.53B | 9.04B | 8.68B | 8.43B | |||||||||||||
| United States Growth | 29.81% | 29.15% | 25.71% | 21.19% | 16.25% | 12.49% | 10.49% | 10.40% | |||||||||||||
| EMEA | 3.35B | 3.33B | 3.27B | 3.23B | 3.15B | 3.05B | 2.95B | 2.86B | |||||||||||||
| EMEA Growth | 6.36% | 9.26% | 11.03% | 13.06% | 13.90% | 13.75% | 12.70% | 13.02% | |||||||||||||
| APAC | 2.98B | 2.86B | 2.74B | 2.69B | 2.62B | 2.54B | 2.50B | 2.40B | |||||||||||||
| APAC Growth | 13.76% | 12.38% | 9.56% | 11.83% | 12.75% | 13.47% | 16.50% | 13.52% | |||||||||||||
| LACA | 654.00M | 638.00M | 631.00M | 625.00M | 618.00M | 605.00M | 583.00M | 560.00M | |||||||||||||
| LACA Growth | 5.83% | 5.45% | 8.23% | 11.61% | 15.73% | 19.33% | 19.71% | 19.66% | |||||||||||||
| Specialty Pharma | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 191.00M | 219.00M | 241.00M |
Operating Expense Breakdown
| Period Ending | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative | 6.67B | 6.49B | 6.22B | 5.98B | 5.75B | 5.43B | 5.34B | 5.19B | |||||||||||||
| Selling, General, and Administrative Growth | 15.91% | 19.44% | 16.45% | 15.30% | 15.62% | 11.66% | 14.20% | 14.82% | |||||||||||||
| Research and Development | 1.94B | 1.84B | 1.69B | 1.62B | 1.52B | 1.47B | 1.44B | 1.42B | |||||||||||||
| Research and Development Growth | 27.91% | 25.07% | 17.24% | 14.20% | 9.91% | 7.55% | 7.68% | 6.95% | |||||||||||||
| Amortization | 894.00M | 874.00M | 862.00M | 857.00M | 840.00M | 843.00M | 840.00M | 829.00M | |||||||||||||
| Amortization Growth | 6.43% | 3.68% | 2.62% | 3.38% | 2.44% | 3.56% | 3.96% | 3.24% | |||||||||||||
| Asset and Goodwill Impairment | - | 434.00M | - | 445.00M | - | 459.00M | - | - | 190.00M | 386.00M | - | - | 457.00M | 377.00M | - | 509.00M | - | - | |||
| Asset and Goodwill Impairment Growth | - | 12.44% | - | -2.63% | - | 21.75% | - | - | -62.67% | -27.31% | - | - | 4.58% | -36.10% | - | - | - | - | |||
| Litigation-related Net Charges | - | - | - | - | - | - | - | - | 190.00M | - | - | 599.00M | - | 472.00M | - | 448.00M | - | 580.00M | 505.00M | - | - |
| Litigation-related Net Charges Growth | - | - | - | - | - | - | - | - | -67.24% | - | - | 18.61% | - | - | - | - | - | - | - | - | - |
| Restructuring Net Charges | 89.00M | 105.00M | 23.00M | 16.00M | 31.00M | 38.00M | 53.00M | 70.00M | |||||||||||||
| Restructuring Net Charges Growth | 187.10% | 176.32% | -56.60% | -77.14% | -45.61% | -17.39% | 29.27% | 180.00% | |||||||||||||
| Royalty Expense | 50.00M | 43.00M | 38.00M | 34.00M | 36.00M | 42.00M | 45.00M | 46.00M | |||||||||||||
| Royalty Expense Growth | 38.89% | 2.38% | -15.56% | -26.09% | -23.40% | -10.64% | -2.17% | -2.13% | |||||||||||||
| Loss on Disposal of Assets | - | - | - | - | - | - | - | - | - | - | - | 34.00M | - | - | - | 18.00M | - | - | - | - | - |
| Contingent Consideration Net Expense | 10.00M | -24.00M | -17.00M | -5.00M | 10.00M | 45.00M | 62.00M | 57.00M | - | ||||||||||||
| Contingent Consideration Net Expense Growth | - | - | - | - | - | 150.00% | 77.14% | 62.86% | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.